Tzimas G, Collins M D, Nau H
Institut für Toxikologie und Embryopharmacologie, Freie Universität Berlin, Germany.
Toxicol Appl Pharmacol. 1995 Jul;133(1):91-101. doi: 10.1006/taap.1995.1130.
In mice and rats, 13-cis-retinoic acid (13-cis-RA) has a much lower teratogenic potency than all-trans-retinoic acid (all-trans-RA). Previous studies on Gestational Day (GD) 11 or 12 (in mice or rats, respectively) showed a limited transfer of 13-cis-RA to the embryo, in contrast to the efficient transplacental passage of all-trans-RA. In the present study we examined if the distribution between maternal circulation and embryo of 13-cis- and all-trans-RA as well as their metabolites is different at gestational times when the placenta is developing from a choriovitelline to a chorioallantoic type. In the first experiment, 13-cis-RA was administered orally to pregnant rats (75 mg/kg/day) daily, from either GD 7 to 12 or 11 to 16. In the second experiment, 13-cis-RA or all-trans-RA was given orally to pregnant mice once on either GD 11 or 14, at two dose levels (10 and 100 mg/kg). HPLC analysis of plasma and embryo samples collected at various time points post-treatment showed that 13-cis-RA was predominantly metabolized to its beta-glucuronide (13-cis-RAG) while all-trans-RA was primarily biotransformed to all-trans-4-oxo-RA and to a lesser extent to all-trans-RAG. 13-cis-RA showed a more efficient transplacental passage to the rat embryo on GD 16 than on GD 12, as indicated by higher ratios of embryonic to maternal plasma concentrations (E/M concentration ratio) on GD 16 vs. GD 12 and its E/M ratio of area-under-the-concentration-time-curve values (E/M AUC ratio; twofold higher on GD 16 vs. GD 12). In the mouse, the E/M concentration ratio of 13-cis-RA was significantly higher on GD 14 than on GD 11 only at the low dose. On the other hand, all-trans-RA and all-trans-4-oxo-RA showed an efficient transfer to the mouse embryo at both gestational times. In both species, 13-cis- and all-trans-RAG embryonic concentrations on the later gestational days exceeded significantly the corresponding ones on the earlier gestational days which resulted in far higher E/M concentration and AUC ratios for each of these metabolites on the later vs earlier gestational days. This may result from a more efficient placental transfer of the RAGs during later gestational stages and/or higher capacity of the late embryo or other conceptal tissues to biotransform RAs in situ to their glucuronides.(ABSTRACT TRUNCATED AT 400 WORDS)
在小鼠和大鼠中,13-顺式维甲酸(13-cis-RA)的致畸效力远低于全反式维甲酸(all-trans-RA)。先前针对妊娠第11天或第12天(分别针对小鼠或大鼠)的研究表明,与全反式维甲酸高效的胎盘转运相比,13-顺式维甲酸向胚胎的转运有限。在本研究中,我们探究了在胎盘从卵黄囊绒毛膜型发育为尿囊绒毛膜型的妊娠时期,13-顺式维甲酸和全反式维甲酸及其代谢产物在母体循环与胚胎之间的分布是否存在差异。在第一个实验中,从妊娠第7天至12天或第11天至16天,每天给妊娠大鼠口服13-顺式维甲酸(75毫克/千克/天)。在第二个实验中,在妊娠第11天或第14天,以两种剂量水平(10和100毫克/千克)给妊娠小鼠口服一次13-顺式维甲酸或全反式维甲酸。对处理后不同时间点采集的血浆和胚胎样本进行高效液相色谱分析表明,13-顺式维甲酸主要代谢为其β-葡萄糖醛酸苷(13-cis-RAG),而全反式维甲酸主要生物转化为全反式-4-氧代维甲酸,较少转化为全反式-RAG。13-顺式维甲酸在妊娠第16天向大鼠胚胎的胎盘转运比在妊娠第12天更高效,这表现为妊娠第16天与第12天相比,胚胎与母体血浆浓度之比(E/M浓度比)更高,且其浓度-时间曲线下面积值的E/M比(E/M AUC比;妊娠第16天比第12天高两倍)也更高。在小鼠中,仅在低剂量时,13-顺式维甲酸的E/M浓度比在妊娠第14天显著高于妊娠第11天。另一方面,全反式维甲酸和全反式-4-氧代维甲酸在两个妊娠时期均显示出向小鼠胚胎的高效转运。在这两个物种中,妊娠后期的13-顺式和全反式-RAG胚胎浓度均显著超过早期妊娠时的相应浓度,这导致这些代谢产物在妊娠后期与早期相比,E/M浓度和AUC比远更高。这可能是由于妊娠后期胎盘对RAGs的转运更高效和/或晚期胚胎或其他孕体组织将维甲酸原位生物转化为其葡萄糖醛酸苷的能力更强所致。(摘要截选至400字)